Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Sangamo Therapeutics (SGMO) Receivables Refunds (2023 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Receivables Refunds for 3 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • For Q4 2025, Receivables Refunds rose 149.07% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $10.1 million, up 149.07%, while the annual FY2025 figure was $10.1 million, 149.07% up from the prior year.
  • Receivables Refunds hit $10.1 million in Q4 2025 for Sangamo Therapeutics, up from $4.6 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $10.1 million in Q4 2025 and bottomed at $3.1 million in Q4 2023.
  • Average Receivables Refunds over 3 years is $5.1 million, with a median of $4.4 million recorded in 2025.
  • Year-over-year, Receivables Refunds grew 29.52% in 2024 and then skyrocketed 149.07% in 2025.
  • Sangamo Therapeutics' Receivables Refunds stood at $3.1 million in 2023, then increased by 29.52% to $4.1 million in 2024, then surged by 149.07% to $10.1 million in 2025.
  • According to Business Quant data, Receivables Refunds over the past three periods came in at $10.1 million, $4.6 million, and $4.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.